文献速递乳腺乳腺X线

基于乳腺X线影像组学特征与临床特征预测乳腺癌人表皮生长因子受体2(HER2)状态:一项多中心研究

Prediction of human epidermal growth factor receptor 2 (HER2) status in breast cancer by mammographic radiomics features and clinical characteristics: a multicenter study.
PubMed 文献 · Eur Radiol · 2024-01-26

该多中心研究纳入1512例来自两家医院、五种设备的浸润性导管癌(非特殊型)中国女性,采用梯度提升机构建影像组学与多组学模型,术前预测HER2状态。多组学模型在训练、测试及外部验证队列的AUC分别为0.838、0.788、0.722,均持续优于仅用影像组学特征的模型。

要点

  • 多组学模型(影像组学+临床特征)在外部验证队列AUC为0.722(95%CI 0.637-0.811),优于影像组学模型的0.702(95%CI 0.614-0.790)。
  • 影像组学模型在外部验证队列表现欠佳(AUC 0.702,95%CI 0.614-0.790),提示单独使用时泛化能力有限。
  • HER2阳性比例在训练、测试和外部验证队列分别为26.3%、26.3.8%和28.3%,三组间无统计学差异(p=0.842,卡方检验)。

核心结论

  • 基于影像组学特征与临床特征的模型有潜力在多设备、多中心条件下准确预测乳腺癌患者的HER2状态。

研究设计与样本

  • 多中心研究,纳入1512例浸润性导管癌(非特殊型)中国女性,来自两家医院、五种设备(机构A 1332例用于模型训练与测试,机构B 180例作为外部验证队列),采用梯度提升机构建影像组学及多组学模型,以AUC评估模型效能。

关键影像表现/征象

  • 乳腺X线表现与乳腺癌人表皮生长因子受体2(HER2)状态密切相关。
  • 仅基于影像组学特征的模型在外部验证队列中表现欠佳。
  • 结合影像组学特征与临床特征的多组学模型可提高外部数据的预测能力。

诊断标准与关键数值

  • 影像组学模型AUC:训练队列0.814(95%CI 0.784-0.844),测试队列0.776(95%CI 0.727-0.825),外部验证队列0.702(95%CI 0.614-0.790)。
  • 多组学模型AUC:训练队列0.838(95%CI 0.810-0.866),测试队列0.788(95%CI 0.741-0.835),外部验证队列0.722(95%CI 0.637-0.811)。
  • HER2阳性患者数量:训练队列245例(26.3%),测试队列105例(26.3.8%),外部验证队列51例(28.3%),三组间无统计学差异(p=0.842,卡方检验)。

临床应用与阅片要点

  • 作者认为,基于多设备、多中心影像组学特征与临床特征构建的模型,有潜力可靠预测乳腺癌HER2状态,有助于增强模型在真实临床场景中的适用性和泛化能力。
  • 影像组学模型在外部验证队列表现欠佳(AUC 0.702,95%CI 0.614-0.790),结合临床特征的多组学模型可提高外部数据预测能力(AUC 0.722,95%CI 0.637-0.811)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To preoperatively evaluate the human epidermal growth factor 2 (HER2) status in breast cancer using mammographic radiomics features and clinical characteristics on a multi-vendor and multi-center basis.

METHODS: This multi-center study included a cohort of 1512 Chinese female with invasive ductal carcinoma of no special type (IDC-NST) from two different hospitals and five devices (1332 from Institution A, used for training and testing the models, and 180 women from Institution B, as the external validation cohort). The Gradient Boosting Machine (GBM) was employed to establish radiomics and multiomics models. Model efficacy was evaluated by the area under the curve (AUC).

RESULTS: The number of HER2-positive patients in the training, testing, and external validation cohort were 245(26.3%), 105 (26.3.8%), and 51(28.3%), respectively, with no statistical differences among the three cohorts (p = 0.842, chi-square test). The radiomics model, based solely on the radiomics features, achieved an AUC of 0.814 (95% CI, 0.784-0.844) in the training cohort, 0.776 (95% CI, 0.727-0.825) in the testing cohort, and 0.702 (95% CI, 0.614-0.790) in the external validation cohort. The multiomics model, incorporated radiomics features with clinical characteristics, consistently outperformed the radiomics model with AUC values of 0.838 (95% CI, 0.810-0.866) in the training cohort, 0.788 (95% CI, 0.741-0.835) in the testing cohort, and 0.722 (95% CI, 0.637-0.811) in the external validation cohort.

CONCLUSIONS: Our study demonstrates that a model based on radiomics features and clinical characteristics has the potential to accurately predict HER2 status of breast cancer patients across multiple devices and centers.

CLINICAL RELEVANCE STATEMENT: By predicting the HER2 status of breast cancer reliably, the presented model built upon radiomics features and clinical characteristics on a multi-vendor and multi-center basis can help in bolstering the model's applicability and generalizability in real-world clinical scenarios.

KEY POINTS: • The mammographic presentation of breast cancer is closely associated with the status of human epidermal growth factor receptor 2 (HER2). • The radiomics model, based solely on radiomics features, exhibits sub-optimal performance in the external validation cohort. • By combining radiomics features and clinical characteristics, the multiomics model can improve the prediction ability in external data.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Deng Y, Lu Y, Li X, et al. Prediction of human epidermal growth factor receptor 2 (HER2) status in breast cancer by mammographic radiomics features and clinical characteristics: a multicenter study. Eur Radiol. 2024. PMID: 38276982. doi:10.1007/s00330-024-10607-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。